Kolexia
Edeline Veronique Médecine nucléaire
Edeline Veronique
Médecine nucléaire
Hôpital Pitie Salpetriere
Paris, France
41 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Tumeurs du sein Seconde tumeur primitive Récidive tumorale locale Cancers du sein inflammatoires Lymphome malin non hodgkinien Tumeurs de la thyroïde Carcinome pulmonaire à petites cellules

Collaborateurs

Voir plus
Brice Pauline
Brice Pauline
Hôpital Saint-Louis, Paris, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Berriolo-Riedinger Alina
Berriolo-Riedinger Alina
Centre Georges-François Leclerc, Dijon, France
Stamatoullas Aspasia
Stamatoullas Aspasia
Centre Henri-Becquerel, Rouen, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Interim FDG-PET improves treatment failure prediction in primary central nervous system Lymphoma: a LOC network prospective multicentric study.
Neuro-oncology   16 février 2024
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   15 novembre 2023
18FFDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network.
European journal of nuclear medicine and molecular imaging   18 juillet 2023
EARLY FDG-PET ADAPTED TREATMENT OF LIMITED STAGE HODGKIN LYMPHOMA (HL): 10Y LONG TERM FOLLOW-UP ANALYSIS OF THE RANDOMIZED INTERGROUP EORTC/LYSA/FIL H10 TRIAL
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Leukemia & lymphoma   17 août 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   06 janvier 2022
BV-ICE: Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Essai Clinique (Millennium Pharmaceuticals)   06 décembre 2021
Total Metabolic Tumor Volume and Tumor Dissemination Are Independent Prognostic Factors in Advanced Hodgkin Lymphoma
Blood   23 novembre 2021
Apport de la TEP-TDM au 18F-FDG chez des patients avec cancer bronchique non à petites cellules ou mélanome métastatique traités par immunothérapie
Médecine Nucléaire   01 mars 2021
PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study
Blood   05 novembre 2020